Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
NCT06452602Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival up to 2 years. Started Jun 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06452602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452602.